⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
XLO News
Xilio Therapeutics, Inc. Common Stock
Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC
globenewswire.com
XLO
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
XLO
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
globenewswire.com
XLO
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
XLO
Form 8-K
sec.gov
XLO
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
globenewswire.com
XLO
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
XLO
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
globenewswire.com
XLO
Form 8-K
sec.gov
XLO
Form 8-K
sec.gov
XLO
ABBV
GILD